Development of Group B Streptococcal vaccine
NeoStrep is funded by the European Commission FP7 Programme HEALTH
WP3 The vaccine will be targeting women of childbearing age, and the aim is to enrol healthy adult female volunteers in the early clinical trials of the vaccine. Appropriate and slightly expanded safety/toxicity studies compared to vaccines to be tested initially in males only therefore have to be conducted prior to initiation of clinical studies.
Provide sufficient evidence that the vaccine is safe in humans, in order to obtain approval by the regulatory authorities to initiate human clinical testing.
The specific objectives are:
WORK PACKAGE 3